Beylerli, Ozal,
Gareev, Ilgiz,
Musaev, Elmar,
Roumiantsev, Sergey,
Chekhonin, Vladimir,
Ahmad, Aamir,
Chao, Yuan,
Yang, Guang (2025) -tumor barrier (BTB), which limit the efficacy of systemic
therapies. Recent advances in molecular biology
of standardized protocols, optimization of delivery techniques, integration with
combination therapies of the potential of immune system-derived miRNAs to revolutionize CVD management and
therapy, addressing a major